Inhibitors for protein n-terminal methyltransferase and uses thereof
AssigneePurdue Research Foundation
InventorsRong HUANG, Dongxing Chen, Guangping Dong
Life of this patent
Estimating the term…
Abstract
The present invention relates to series of peptidomimetic compounds as an inhibitor targeting protein N-terminal methyltransferase pharmacological pathway. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases caused by abnormal protein methyltransferase pathway, including cancer, inflammation, neurodegenerative and cardiovascular diseases, are within the scope of this disclosure.
Claims20
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound selected from the group consisting of:
(canceled)
(canceled)
(canceled)
A method for treating a patient with a disease caused by abnormal activities of protein methyltransferases (PMTs) comprising the step of administering a therapeutically effective amount of a compound to the patient in need of relief from said disease, wherein said compound has a formula (II):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is an alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl;
- R3 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkylamino, alkylaminoalkyl, or alkylguanidino;
- R4 is hydrogen, an alkyl, alkenyl, alkynyl, acyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, or one to eleven amino acid residues;
- and
- R5 is hydrogen or an alkyl.
Dependencies are inferred from the claim text.